For & Against

What's Next

Greggs is already past its most dangerous tape (the January 2025 profit warning) and into the show-me phase. The January 2026 trading update already set expectations low for FY26 — "profits at a similar underlying level to 2025" — so the next 3–6 months are less about whether the market learns something new and more about whether the first-half print proves the bottom is in.

The market is watching two numbers and two prices. The numbers are H1 FY26 operating margin and H1 LFL. The prices are the weekly close above £17.50 (reclaims the 100-day, breaks the sequence of lower highs since January 2025) and the daily close below £15.00 (re-opens the July 2025 £14.07 low). Everything else — AGM, Derby commissioning, Q1 update — is either low-information or a leading indicator for those four prints.

For / Against / My View

For

The vertical-integration moat is still showing up in the numbers. Greggs' 61.5% gross margin is roughly double the listed UK food-service cohort (Compass 33%, SSP 47%, Domino's 46%) and has been stable across two decades including through inflation shocks. That is the single best evidence the business has something competitors cannot replicate without owning their own bakeries.

Valuation compression has reached levels only 2008 produced. EV/EBITDA of 6.1x is a full 1.8 turns below the 20-year mean (7.9x) and well under half the 5-year average; the quality-score / fair-value framework flags a discount that on the last comparable occasion (2008–2009) preceded a 5x move over the next five years. Cheap is not the same as attractive, but this is the deepest discount the business has printed outside a genuine crisis.

The capex-to-FCF flip is dated, not theoretical. Capex went from £54M in FY21 to £285M in FY25; management has now explicitly called "past the peak of investment," Derby comes online mid-2026, Kettering in 2027. If the build lands on schedule — and the guidance-track record on physical projects has been clean — then 2027 FCF should rebuild toward the £150–200M corridor that used to fund specials, which is what the current 4.1% yield is not pricing.

Pay discipline and balance-sheet conservatism limit downside. Bonus paid out at 53% of max (not 85%) when targets weren't met, no dilution, £47M net cash even after the capex peak, Altman Z still 3.5. This is not a company that will be pushed into value-destructive action if the slowdown extends — the cash return policy bends before the strategy does.

Against

The "doubling sales by 2026" anchor has been quietly dropped. It dominated CEO letters through 2024 and is absent from the FY25 letter — replaced by vaguer "medium-term opportunities" language. Greggs would need £2.46bn in 2026 against a base of £2.15bn plus flat-profit guidance; the math no longer works, and the way management has handled the walk-back (soft fade rather than formal retraction) is the weakest chapter in an otherwise clean credibility history.

ROCE compression is the central unanswered question. The drop from 32% (FY24) to 21% (FY25) is partly mechanical (distribution-centre capex sitting in the denominator pre-revenue) but the margin piece is not mechanical — it's UK wage inflation, National Insurance (~£45M annual cost step-up), and the reality that Greggs has almost no pricing power above its value perception. If ROCE settles in the high teens rather than rebuilding to the high-20s, the 25x-type multiple the stock used to earn does not come back.

Skin in the game is a rounding error. The CEO holds ~£0.5m of stock against £1.8m annual comp; all insiders combined hold roughly 0.1% of the company; the only recent open-market buy by management was a £20k token from the Chair. Combined with the CFO succession turnover and Audit Chair handover inside 18 months, the people running the business are not personally invested at a level where this looks like anything other than professional stewardship — which is fine in a calm market but thin if a second leg down tests governance resolve.

The tape says the market does not believe the recovery yet. Three years of relative underperformance vs the UK broad market, price 27% below the 52-week high, four of the last five high-volume days were panic sells, and the 50-day SMA is still sub-200 with the death cross unresolved. Technicals can be wrong, but the weight of the evidence is a counter-trend rally inside a broader stall, not a new leg.

My View

Slight lean against, but it is a close call and I would not fight the other side hard. The valuation and the capex-flip arguments are real — 6.1x EV/EBITDA on a 20%-plus ROCE business with £47M net cash is not a set-up that usually produces bad five-year returns. What holds me back is the combination of the quietly-abandoned doubling target, the fact that H1 FY26 margin is the load-bearing print and it is four months away, and a tape that is clearly not ready to pay up in front of it. I'd rather wait and pay more above £17.50 with a 9%-plus H1 margin in hand than average in here and be the shareholder who finds out in August that 8.7% was the ceiling, not the floor. The one data point that would flip the view now rather than later is an early-Q2 LFL print materially above 3% — that would make the cyclical-pause reading far more credible than the structural-reset reading, and would make the current price the cheap option it looks like on paper.